Fennec Pharmaceuticals Reports Robust Q1 Sales Growth, Profitability, and Strong Operating Cash Flow

summarizeSummary

Fennec Pharmaceuticals reported robust first-quarter results with a 73% year-over-year increase in PEDMARK® sales, a shift to net income, and positive operating cash flow, reinforcing its strong commercial trajectory and long-term market exclusivity.

check_boxKey Events

• Record Q1 Net Product Sales

  Net product sales for PEDMARK® increased 73% year-over-year to $15.1 million for the first quarter of 2026, driven by increased market penetration and access.

• Shift to Net Income and Positive Operating Cash Flow

  The company reported a net income of $0.201 million for Q1 2026, a significant improvement from a net loss of $1.165 million in Q1 2025. Net cash provided by operating activities was $2.379 million, reversing a negative cash flow from the prior year.

• Patent Litigation Settlement Confirmed

  The settlement agreement with Cipla, announced on March 16, 2026, is reiterated, confirming PEDMARK®'s market exclusivity in the U.S. until September 1, 2033.

• Sales Organization Expansion Drives Expenses

  Selling and marketing expenses rose to $11.422 million in Q1 2026 from $3.227 million in Q1 2025, primarily due to higher commercial headcount and related expenses to support U.S. market expansion.

auto_awesomeAnalysis

Fennec Pharmaceuticals delivered a strong first quarter, with net product sales surging 73% year-over-year to $15.1 million, indicating significant market penetration for PEDMARK®. The company successfully shifted from a net loss to a net income of $0.201 million and generated positive operating cash flow of $2.379 million, a substantial improvement from a negative cash flow in the prior year. This financial turnaround is further bolstered by the confirmed patent litigation settlement with Cipla, extending PEDMARK®'s market exclusivity until September 2033, which de-risks future revenue streams. Increased selling and marketing expenses reflect the expansion of the sales organization, driving this growth. While the equity incentive plan approved last year allows for significant potential dilution, the current financial performance and strategic positioning are highly positive.